OLaGA Research Center
Pago Pago, American Samoa
NCT Number: NCT05356884
The goal of this project is to test the feasibility, acceptability, and preliminary efficacy of an adolescent-mediated intervention designed to improve the glycemic control and self-care practices of a parent/grandparent. The preliminary impact of the intervention on adult glycemic control (HbA1c) and self-care behaviors, as well as adolescent risk factors, will be explored with the goal of informing future programs that can be scaled to reduce diabetes burden and eliminate health disparities among at risk, ethnic minority groups.
This study is active but is not currently recruiting participants.
Notify Me14 year and older
All sexes
Interventional
Not applicable
Pago Pago, American Samoa
The number of individuals diagnosed with Type 2 Diabetes in the United States (US) has more than doubled since 2000 to over 30 million, with an additional 84.1 million living with prediabetes. One minority group at particular risk is Pacific Islanders (PIs), who are at disproportionate risk and face many barriers (structural and cultural) to engaging in prevention or self-care. To address the critical need for diabetes prevention and treatment programs that target PIs, and building on the family-centered culture, the objective of this project is to pilot test and evaluate a randomized controlled trial of an adolescent-mediated intervention designed to improve the glycemic control and self-care practices of a paired, adult family member with diagnosed diabetes. Dyads (n=160 dyads; an adolescent without diabetes and a parent/grandparent diagnosed with diabetes who share a household) will be randomized. Adolescents will receive either a six-month diabetes intervention or a leadership and life skills-focused control curriculum in groups (n=10 participants in each group). Aside from planned research assessments there will be no contact with the adults in the dyad, who will proceed with their usual diabetes care. To test the hypothesis that adolescents receiving the intervention will be effective conduits of diabetes knowledge and will support their paired adult in the adoption of self-care strategies, the primary efficacy outcomes will be adult glycemic control and cardiovascular risk factors (BMI, blood pressure, waist circumference). Secondarily, since exposure to the intervention may encourage positive behavior change in the adolescent themselves similar outcomes will be measured in the adolescents. Outcomes will be measured at baseline, at the end of the active intervention phase (six months post-randomization) and at 12-months post-randomization, to examine maintenance of intervention effects in the absence of contact. To determine potential for long-term sustainability and scale up, program acceptability, feasibility, fidelity, reach, and cost will be examined. Successful completion of the study aims and proof of efficacy would produce an innovative, scalable program with high potential for replication in other similar, low-resource, family-centered, ethnic minority groups across the US who are the ideal beneficiaries of innovations to reduce chronic disease risk and eliminate health disparities.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adolescent
Adult
Exclusion criteria
Adolescent
Adult
A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)
Time frame: 0 - 6 months
Glycated hemoglobin (marker of long term glycemic control)
Time frame: 0 - 12 months
Glycated hemoglobin (marker of long term glycemic control)
Time frame: 6 - 12 months
Glycated hemoglobin (marker of long term glycemic control)
Time frame: 0 - 6 months
Body mass index (measure of weight control)
Time frame: 0 - 12 months
Body mass index (measure of weight control)
Time frame: 6 - 12 months
Body mass index (measure of weight control)
Time frame: 0 - 6 months
Blood Pressure (marker of hypertension risk)
Time frame: 0 - 12 months
Blood Pressure (marker of hypertension risk)
Time frame: 6 - 12 months
Blood Pressure (marker of hypertension risk)
Time frame: 0 - 6 months
Waist circumference (measure of weight control)
Time frame: 0 - 12 months
Waist circumference (measure of weight control)
Time frame: 6 - 12 months
Waist circumference (measure of weight control)
Time frame: 0 - 6 months
Glycated hemoglobin (marker of long term glycemic control)
Time frame: 0 - 12 months
Glycated hemoglobin (marker of long term glycemic control)
Time frame: 6 - 12 months
Glycated hemoglobin (marker of long term glycemic control)
Time frame: 0 - 6 months
Body mass index (measure of weight control)
Time frame: 0 - 12 months
Body mass index (measure of weight control)
Time frame: 6 - 12 months
Body mass index (measure of weight control)
Time frame: 0 - 6 months
Blood Pressure (marker of hypertension risk)
Time frame: 0 - 12 months
Blood Pressure (marker of hypertension risk)
Time frame: 6 - 12 months
Blood Pressure (marker of hypertension risk)
Time frame: 0 - 6 months
Waist circumference (measure of weight control)
Time frame: 0 - 12 months
Waist circumference (measure of weight control)
Time frame: 6 - 12 months
Waist circumference (measure of weight control)
Yale University
Other
An Adolescent-mediated Intervention to Improve Diabetes Prevention and Management in Pacific Islander Families
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05198765
Body Weight, Diabetes Mellitus
Minneapolis, Minnesota, United States
View Trial DetailsNCT02710370
Body Weight, Diabetes Mellitus
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06641765
Autoimmune Diseases, Continuous Glucose Monitoring
Copenhagen, Denmark
View Trial DetailsNCT00005487
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details